Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, PBMCs from women with PCOS showed reduced TNF-α production over time, potentially limiting their antitumor response to breast cancer cell lines compared to healthy controls.

In this randomized trial, bicalutamide was found to improve hair count and shaft diameter more than spironolactone in women with Female Pattern Hair Loss over 24 weeks, although no significant differences were observed in clinical endpoints between the two treatments.

This review discusses the mechanism and side effects of smoothened inhibitors for advanced basal cell carcinoma, reporting no new clinical results and highlighting current management strategies for these adverse events.

This study found that administering chemotherapy to premenopausal women with Stage II breast cancer significantly improved disease-free intervals and increased survival, while postmenopausal women receiving sufficient doses also saw prolonged disease-free periods.

This study found that wedelolactone, a natural compound from plants, inhibited breast cancer-mediated osteoclast differentiation and activity in vitro, suggesting its potential as a therapy for bone destruction in breast cancer bone metastasis.

This study reported that ritlecitinib 50 mg and baricitinib 4 mg showed similar efficacy in treating severe alopecia areata, with no significant difference in hair regrowth outcomes at Week 24, but there remains considerable uncertainty and a need for further research.

This study found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg for treating severe alopecia areata at Weeks 24 and 52, potentially influencing reimbursement decisions.

Baricitinib helps with early hair regrowth in people with alopecia areata.

This review discusses the pharmacological properties of progestins used in contraception and hormone replacement therapy, focusing on drospirenone's unique effects, but reports no new experimental findings.

This phase I study reported that ETC-159, targeting Wnt signalling, showed tolerable safety profiles at doses that inhibit its pathway, though bone turnover markers increased, warranting early and regular monitoring. No tumor responses were observed, but two patients achieved stable disease for several cycles.

This article discusses the role of insulin resistance in cardiovascular risk and suggests that lifestyle changes may be more beneficial than metformin in managing polycystic ovary syndrome; it reports no new clinical results.

This study found that specific steroids, particularly 5 and 7b, decreased growth of prostate and seminal vesicles and bound to the androgen receptor, showing comparable pharmacological activity to finasteride.

This review discusses the use of acarbose for managing polycystic ovary syndrome and notes positive but limited evidence from small trials, indicating a need for more rigorous studies.

This study found that combining sorafenib with Platycladus orientalis leaf extract effectively suppressed cervical cancer cell growth by increasing tumor suppressor gene expression and reducing anti-apoptotic gene expression, suggesting a potential rationale for further clinical trials.

This review found that fulvestrant is well tolerated in postmenopausal women with hormone receptor-positive advanced breast cancer, showing lower incidence of joint disorders than non-steroidal aromatase inhibitors.

This study suggests that berberine may offer multiple benefits for women with polycystic ovary syndrome by improving metabolic and hormonal profiles, though further research is needed on its long-term effects on reproductive outcomes.

This study found that bicalutamide mesotherapy resulted in subtle hair density improvements and was well tolerated by premenopausal women with androgenetic alopecia.

This article reviews the complex nature and diagnostic criteria of polycystic ovary syndrome, and discusses its treatment options without reporting any new clinical results.

In this case report, four sessions of the Broad Ligament Maneuver were associated with improvements in ovarian function and regression of PCOS symptoms, including normalizing menstrual flow and decreasing hirsutism.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.

In this study, 12 months of cyproterone acetate and ethinyl oestradiol treatment significantly reduced hair growth rate and certain hormone levels in hirsute women, though hair density and prolactin levels remained unchanged.

This study found that Litfulo improved hair regrowth in patients aged 12 and older with severe alopecia areata but did not meaningfully improve anxiety or depression symptoms compared to placebo.

This study examined the safety profile of ritlecitinib, a drug for alopecia areata, and found that it does not cause significant QTc prolongation or severe lymphopenia, with no unique safety risks expected in adolescents.

This study found that the combination of cyproterone acetate and ethinyl estradiol improved hirsutism and acne in women, with SH 8.1041 showing significant results and both treatments being generally well-tolerated.

This study found that medroxyprogesterone acetate and ethinyl estradiol with drospirenone were the most frequently prescribed medications for PCOS, with some patients experiencing drug changes or discontinuation due to side effects or therapeutic failure.

This study reports the discovery of LX-38, a novel non-steroidal drug candidate that may offer safer treatment for conditions like Benign Prostatic Hyperplasia by avoiding hormonal side effects associated with current therapies.

This study found that self-monitoring blood pressure among pregnant women with hypertension did not significantly improve clinical outcomes compared to usual care, though women reported positive cognitive and emotional responses.

This study found that the progesterone metabolite 3α-THP increased the proliferation and gene expression of human glioblastoma cells, suggesting a role in tumor progression.

This article reviews the negative effects of androgenic disorders and highlights that newer oral contraceptives with less androgenic progestins may reduce these effects and improve compliance, but it reports no new results.